Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Specialties
Hematology
Oncology
Musculoskeletal Disorder
Rare Disease
Metabolic Disorder
Cardiovascular Disease
Ophthalmology
Neurology
Infectious Disease
View all Specialties
Technologies
Cell Therapy
MSC
iPSC
Gene Therapy
Genome Editing
Extracellular Vesicles
CAR-T Therapy
TCR Therapy
Tissue-Engineering & Biomaterials
View all Technologies
Topics
Treatment
Immuno-Oncology
Trial Updates
Perspectives
Manufacturing
COVID-19
View all Topics
Conferences
ASH 2022
TCT 2022
Meeting on the Med 2022
ICLE 2022
Advanced Therapies Week 2022
TERMIS 2021
ESGCT 2021
Meeting on the Mesa 2021
Advanced Therapies 2021
View all Conferences
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Matthew Durdy
2:07
Addressing remaining barriers to the commercialization of ATMPs
Matthew Durdy
• 6 Oct 2021
1:44
The evolving landscape of autologous and allogeneic therapies
Matthew Durdy
• 6 Oct 2021
2:21
An update on the UK Cell and Gene Therapy Catapult
Matthew Durdy
• 6 Oct 2021
1:44
What can the advanced therapies industry learn from the COVID-19 pandemic?
Matthew Durdy
• 6 Oct 2021
1:34
The current landscape of advanced therapies in the UK
Matthew Durdy
• 6 Oct 2021
4:25
Building the advanced therapies workforce in the UK
Matthew Durdy
• 9 Apr 2021
3:31
The state of investment in cell & gene therapy
Matthew Durdy
• 9 Apr 2021
3:35
Tackling manufacturing challenges in advanced therapies
Matthew Durdy
• 9 Apr 2021
4:03
Harmonizing standards in the advanced therapy industry
Matthew Durdy
• 9 Apr 2021
